 | |
15 May: Call for abstracts for the 32nd Alzheimer Europe Conference is closed
 The call for abstracts is now closed for the 32nd Alzheimer Europe Conference, which will take place in Bucharest, Romania, under the banner “Building Bridges”. We are pleased to have received almost 270 abstracts, all of which are now being reviewed by the Scientific Committee. All submitting authors will be informed of the Committee's decision in mid-June.
Read more »
|
27 May: World Health Assembly passes neurological conditions action plan
 Delegates at the 75th World Health Assembly have approved a new intersectoral global action plan on epilepsy and other neurological disorders (including stroke, migraine, dementia and meningitis) that aims to improve access to care and treatment for people living with these conditions, while preventing new cases and promoting brain health and development across the life course.
Read more »
|
|
|
|
|
Alzheimer Europe’s 
Alzheimer Europe co-organised a webinar with the European Federation of Neurological Alliances (EFNA) and GAMIAN-Europe, on "Patient involvement in Brain Health: Safeguarding the future of Brain Health for patients". A joint Call to Action was also launched, highlighting the need for improved Patient Involvement in brain health research in Europe. Helen Rochford-Brennan was among the speakers, highlighting that people with dementia must be equal partners in research.
The European Working Group of People with Dementia (EWGPWD) met face-to-face this month, for the first time in over two years. They worked on several projects, within the framework of Public Involvement. At the meeting, Chris Roberts was re-elected as Chairperson, for the next term of office (starting from October). The group also discussed the organisation of its special symposium at the 32nd Alzheimer Europe Conference.
It has been 20 years since the last approval of an Alzheimer’s medicine by the European Medicines' Agency, meaning that people living in Europe affected by Alzheimer’s disease (AD) have been waiting to gain access to better treatments for two decades. With Biogen’s recent withdrawal of its marketing authorisation application for aducanumab, the wait goes on.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Commission. Neither the European Union nor the granting authority can be held responsible for them.